OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
Rhea-AI Summary
OS Therapies (NYSE: OSTX) completed a $5.25 million registered direct offering on April 2, 2026, issuing common stock (or pre-funded warrants) and accompanying warrants at a $1.40 per-share exercise/purchase price.
The company expects approximately $4 million of additional non-dilutive VAT refunds and R&D tax credits via its U.K. subsidiary in 2Q-26 and 2H-26, and says proceeds plus those funds are expected to provide cash runway into 2027 while it pursues H2-2026 regulatory interactions and potential approvals for OST-HER2.
AI-generated analysis. Not financial advice.
Positive
- $5.25M capital raised via registered direct offering
- Expecting approximately $4M non-dilutive VAT and R&D refunds
- Proceeds plus refunds expected to provide cash runway into 2027
- OST-HER2 pursuing U.S./U.K./EU approvals in H2 2026
- Eligible for a Priority Review Voucher under RPDD if BLA granted
Negative
- Funding plan depends on timing of ~$2M VAT refunds in 2Q-26 and ~$2M R&D credits in 2H-26
- No assurance company would realize comparable $205M PRV value if sold
News Market Reaction – OSTX
On the day this news was published, OSTX declined 6.62%, reflecting a notable negative market reaction. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $53.77M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers showed mixed moves: ANL +5.55%, IMMX +5.18%, ACET +2.64%, ATHE +1.29%, while BYSI slipped 0.29%. Momentum scanner flags both an advancing peer (ANL) and a declining one (BYSI), suggesting OSTX’s financing news is more stock-specific than part of a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings & data | Positive | +6.0% | Full-year 2025 results and Phase 2b data submitted for FDA pre-BLA meeting. |
| Mar 27 | Phase 3 planning | Positive | +2.9% | Regulators granted meetings to review global confirmatory Phase 3 design for OST-HER2. |
| Mar 25 | EMA ATMP status | Positive | +4.3% | EMA granted ATMP designation, supporting conditional authorization and reimbursement routes. |
| Mar 09 | Pre-BLA upgrade | Positive | +8.9% | FDA elevated OST-HER2 meeting to Type B pre-BLA, reinforcing Accelerated Approval path. |
| Feb 17 | Regulatory update | Positive | -0.8% | Global regulatory timetable and confirmatory trial plans outlined for OST-HER2. |
Recent regulatory and clinical updates have generally seen positive price follow-through, with only one modest divergence.
Over recent months, OS Therapies has steadily advanced OST-HER2 toward potential approvals. On Feb 17, 2026, it detailed global regulatory plans, but shares slipped 0.82%. Subsequent news saw stronger alignment: a Type D meeting elevated to a Type B pre-BLA meeting on Mar 9 (+8.92%), EMA ATMP designation on Mar 25 (+4.35%), multi-agency Phase 3 design meetings on Mar 27 (+2.92%), and full-year 2025 results plus pre-BLA data submission on Mar 31 (+6.02%). Today’s capital raise fits into this funding-and-regulation narrative.
Regulatory & Risk Context
The company has an effective Form S-3 shelf filed on Aug 8, 2025, allowing issuance of up to $100,000,000 in securities and a related at-the-market prospectus for up to $18,000,000 of common stock. Recent prospectus supplements (424B5 and 424B7) show active use of this shelf, enabling additional equity or warrant-based financing similar to today’s registered direct offering.
Market Pulse Summary
The stock moved -6.6% in the session following this news. A negative reaction despite added cash fits a pattern where equity raises highlight financing risk alongside clinical progress. The company tapped its shelf for a $5.25M registered direct (about $4.7M net) plus warrant coverage, on top of prior convertible notes and resale registrations. While roughly $4M in non-dilutive U.K. funds is expected, investors may focus on ongoing dilution capacity under the $100,000,000 shelf and existing warrant overhang.
Key Terms
registered direct offering financial
pre-funded warrants financial
biologics license application (bla) regulatory
accelerated approval program regulatory
conditional marketing authorisations (cmas) regulatory
orphan drug designation (odd) regulatory
rare pediatric disease designation (rpdd) regulatory
priority review voucher (prv) regulatory
AI-generated analysis. Not financial advice.
- Company expects approximately
$2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26 - Company expects to receive approximately
$2 million in non-dilutive R&D tax credits repayable to the company in cash from its U.K. subsidiary in 2H-26 - Offering net proceeds, together with funds expected to be received via U.K. subsidiary, expected to provide cash runway into 2027
- Company expects to receive approvals in the U.S., U.K. and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma in the second half of 2026
New York, New York--(Newsfile Corp. - April 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced it that it has completed a
Additionally, the Company announced that it expects to receive approximately
"This capital raise, together with the non-dilutive funding we expect to receive from our U.K. subsidiary, is expected to support our operations as we advance toward crucial anticipated 2026 regulatory milestones for OST-HER2 in the U.S., U.K. and Europe, including early market access authorizations and potential eligibility for a Priority Review Voucher (PRV) under our Rare Pediatric Disease Designation (RPDD)," said Paul Romness, President & CEO of OS Therapies. "We are now focused on our upcoming regulatory interactions, including planned meetings later this quarter with the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the Australian Therapeutic Goods Administration (TGA) to review our clinical and biomarker data, as well as our proposed confirmatory Phase 3 trial design. We are hopeful these interactions will support market access for osteosarcoma patients beginning in 2027. This funding is also expected to support the initiation of a Phase 3 confirmatory trial, including the planned activation of an initial trial site in Australia, which is part of the requirements for a Biologics License Application (BLA) under the U.S. Accelerated Approval Program (Accelerated Approval) and for Conditional Marketing Authorisations (CMAs) in the U.K. and Europe."
OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and RPDD from the FDA, and ODD, FTD and ATMP from the EMA. Under the RPDD program, if the Company receives a BLA in the United States, it will become eligible to receive a PRV that it intends to sell, subject to market conditions. The most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of
The securities described above were offered pursuant to a "shelf" registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025. The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered were filed with the SEC and are available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting Ceros Financial Services, Inc. at 1445 Research Boulevard, Rockville, Maryland 20850, or e-mail Ahmed Gheith, Managing Director at Ceros at agheith@cerosfs.com.
No Offer to Sell or Solicit
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in listeria-based cancer immunotherapies. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD and ATMP from the European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study and the overall survival (OS) secondary endpoint. The Company anticipates receiving a Biologics License Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving Conditional Marketing Authorisations from the U.K.'s Medicines and Healthcare products Regulatory Agency and the EMA for OST-HER2 in 2026. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. The Company also anticipates reading out data from a Phase 1b study of OST-504 in castration resistant prostate cancer in the first half of 2026.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to our expected to provide cash runway into 2027, the intended use of net proceeds from the offering, the potential approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
media@ostherapies.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291086